The BRAIN Act would create and expand several federal programs aimed at improving research, treatment development, awareness, and survivorship care for brain tumors, especially glioblastoma. It directs the National Institutes of Health to support a Glioblastoma Therapeutics Network to move promising therapies from preclinical work into early-phase human trials, and to fund multi-institutional research on brain tumor-related cellular immunotherapy, including CAR-T approaches. The bill also authorizes NIH pilot programs to study better monitoring and care models for adult and pediatric brain tumor survivors across their lifespan, including care coordination, psychosocial support, and transition from oncology to primary and specialty care.
In addition to research funding, the bill would require greater transparency around NIH-funded brain tumor biospecimen collections by creating a searchable public reporting system for tissue and fluid samples used in research. It also directs the Department of Health and Human Services to run a national public awareness campaign on cancer clinical trials and biomarker testing, with targeted outreach to higher-risk populations and rural communities, and to fund demonstration projects that test outreach and education strategies for patients, caregivers, and clinicians. Finally, the bill requires FDA guidance to reduce the exclusion of brain tumor patients and patients with rare and recalcitrant cancers from clinical trials for other indications.
The bill would amend the Public Health Service Act to add new NIH research authorities, public reporting requirements, and HHS outreach programs, while also directing FDA to issue guidance on clinical trial eligibility. It authorizes appropriations of $50 million annually for the Glioblastoma Therapeutics Network, $10 million annually for brain tumor cellular immunotherapy, $10 million over fiscal years 2026-2030 for the awareness campaign and demonstration projects, and $5 million annually for survivorship pilot programs. If enacted, it would expand federal involvement in brain tumor research infrastructure, patient education, biospecimen transparency, and survivorship care, affecting NIH, NCI, HHS, FDA, researchers, health care providers, patients, and caregivers.
The bill appears broadly bipartisan and supportive in tone, with introduction by Senators Blumenthal, Rounds, Reed, and Barrasso indicating cross-party backing. The findings section frames brain tumors as a serious unmet medical need with stagnant survival outcomes, and the bill’s structure emphasizes research acceleration, patient access, and improved care coordination rather than regulatory restriction. No committee transcript or vote record is available here, so there is no evidence of recorded opposition in the provided materials.
The main potential points of contention are likely to be the new federal spending commitments, the reporting burden on individuals and entities maintaining NIH-funded biospecimen collections, and the FDA/HHS directives that could affect clinical trial design and eligibility standards. Researchers or institutions may be concerned about compliance and oversight requirements, while patient advocates are likely to support the transparency, access, and survivorship provisions. The bill also includes a funding-withholding mechanism for repeated or egregious biospecimen reporting violations, which could draw scrutiny from affected research entities.